Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.

Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
J Clin Psychiatry. 2020 Jan 28;81(2):
Authors: Citrome LL
Abstract
Valbenazine and deutetrabenazine are FDA-approved as treatment for tardive dyskinesia (TD). Both medications are vesicular monoamine transporter type 2 (VMAT2) inhibitors, and both are effective for reducing TD symptoms. Clinicians need to be aware of the adverse effects of valbenazine and deutetrabenazine, as well as other key differences between the two, in order to individualize treatment. Using the Abnormal Involuntary Movement Scale assists clinicians in assessing progress for each patient. Treating TD effectively with these new medications will reduce the burden of the condition for patients.
PMID: 31995679 [PubMed - in process]

Source: Journal of Clinical Psychiatry - January 31, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research